Artykuły udostępnione publicznie: - Bashkim KadriuWięcej informacji
Niedostępne w żadnym miejscu: 3
The impact of body mass index on the clinical features of bipolar disorder: A STEP‐BD study
B Kadriu, ZD Deng, C Kraus, JN Johnston, A Fijtman, ID Henter, S Kasper, ...
Bipolar disorders 26 (2), 160-175, 2024
Upoważnienia: US National Institutes of Health
1003. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depression
B Kadriu, P Gold, M Lener, E Ballard, M Niciu, P Yuan, D Luckenbaugh, ...
Biological Psychiatry 81 (10), S405-S406, 2017
Upoważnienia: US National Institutes of Health
F171. Ketamine Modulates Kynurenine Pathway in Mood Disorders: A Longitudinal Structural Equation Model
B Kadriu, ZD Deng, C Farmer, P Yuan, E Ballard, B Shovestul, P Gold, ...
Biological Psychiatry 83 (9), S304-S305, 2018
Upoważnienia: US National Institutes of Health
Dostępne w jakimś miejscu: 45
Prognosis and improved outcomes in major depression: a review
C Kraus, B Kadriu, R Lanzenberger, CA Zarate Jr, S Kasper
Translational psychiatry 9 (1), 127, 2019
Upoważnienia: US National Institutes of Health
Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice
F Matrisciano, P Tueting, I Dalal, B Kadriu, DR Grayson, JM Davis, ...
Neuropharmacology 68, 184-194, 2013
Upoważnienia: US National Institutes of Health
Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments
B Kadriu, L Musazzi, ID Henter, M Graves, M Popoli, CA Zarate Jr
International Journal of Neuropsychopharmacology 22 (2), 119-135, 2019
Upoważnienia: US National Institutes of Health, Fondazione Cariplo, Government of Italy
An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes
A Zhubi, M Veldic, NV Puri, B Kadriu, H Caruncho, I Loza, H Sershen, ...
Schizophrenia research 111 (1-3), 115-122, 2009
Upoważnienia: US National Institutes of Health
Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression
MS Lener, B Kadriu, CA Zarate
Drugs 77, 381-401, 2017
Upoważnienia: US National Institutes of Health
Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression
E Maloku, IR Covelo, I Hanbauer, A Guidotti, B Kadriu, Q Hu, JM Davis, ...
Proceedings of the National Academy of Sciences 107 (9), 4407-4411, 2010
Upoważnienia: US National Institutes of Health
Ketamine and serotonergic psychedelics: common mechanisms underlying the effects of rapid-acting antidepressants
B Kadriu, M Greenwald, ID Henter, JR Gilbert, C Kraus, LT Park, ...
International Journal of Neuropsychopharmacology 24 (1), 8-21, 2021
Upoważnienia: US National Institutes of Health
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
EE Acevedo-Diaz, GW Cavanaugh, D Greenstein, C Kraus, B Kadriu, ...
Journal of affective disorders 263, 568-575, 2020
Upoważnienia: US National Institutes of Health
Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals
A Mkrtchian, JW Evans, C Kraus, P Yuan, B Kadriu, AC Nugent, JP Roiser, ...
Molecular psychiatry 26 (7), 3292-3301, 2021
Upoważnienia: US National Institutes of Health, Wellcome Trust
Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales
ED Ballard, JS Yarrington, CA Farmer, MS Lener, B Kadriu, N Lally, ...
Journal of affective disorders 231, 51-57, 2018
Upoważnienia: US National Institutes of Health
A major role for the lateral habenula in depressive illness: physiologic and molecular mechanisms
PW Gold, B Kadriu
Frontiers in Psychiatry 10, 320, 2019
Upoważnienia: US National Institutes of Health
Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects
R Moaddel, M Shardell, M Khadeer, J Lovett, B Kadriu, S Ravichandran, ...
Psychopharmacology 235, 3017-3030, 2018
Upoważnienia: US National Institutes of Health, US Department of Veterans Affairs
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
CA Farmer, JR Gilbert, R Moaddel, J George, L Adeojo, J Lovett, ...
Neuropsychopharmacology 45 (8), 1398-1404, 2020
Upoważnienia: US National Institutes of Health, US Department of Veterans Affairs
The influence of ketamine on drug discovery in depression
C Kraus, D Wasserman, ID Henter, E Acevedo-Diaz, B Kadriu, ...
Drug Discovery Today 24 (10), 2033-2043, 2019
Upoważnienia: US National Institutes of Health
The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response
B Kadriu, CA Farmer, P Yuan, LT Park, ZD Deng, R Moaddel, ID Henter, ...
Molecular psychiatry 26 (8), 4085-4095, 2021
Upoważnienia: US National Institutes of Health
Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder
B Kadriu, PW Gold, DA Luckenbaugh, MS Lener, ED Ballard, MJ Niciu, ...
Molecular psychiatry 23 (7), 1626-1631, 2018
Upoważnienia: US National Institutes of Health
A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression
LT Park, B Kadriu, TD Gould, P Zanos, D Greenstein, JW Evans, P Yuan, ...
International Journal of Neuropsychopharmacology 23 (7), 417-425, 2020
Upoważnienia: US National Institutes of Health, US Department of Veterans Affairs
Informacje na temat publikacji i finansowania automatycznie określa program komputerowy